Immunic Therapeutics was granted a patent in Europe that protects all dosing regimens of its MS therapy vidofludimus calcium through 2038.

A study questioned the use of brain volume loss as a clinical trial endpoint in PPMS after finding a weak link to disability progression.

Briumvi significantly outperformed Aubagio at reducing disease activity in people with highly active relapsing forms of MS, a ...

MS is causing fewer deaths and less disability now than in years past, and the trend will likely continue in the coming years, a study found.

Columnist Desiree Lama finds herself having to argue that a medicine that she has been taking for migraines for years is still needed.

A Phase 1 trial testing TG Therapeutics' CAR T-cell therapy azer-cel in progressive forms of MS is now recruiting across ...

Guest writer Reché Jones says it took her years to be diagnosed with relapsing-remitting MS. Now she plans to "keep moving." ...

When guest writer Antonio Perez turned to social media to learn about MS, he saw a need to help other young people navigate ...

For Izzy Abbass, who grew up around mountains, climbing them, and overcoming hurdles with MS, is easier with good support.

Subtle drops in activity levels detected by wrist-worn sensors may predict worsening disability in MS patients, per a study.

As columnist Ahna Crum marveled at the feats of Olympic medalists, she decided to grab a pair of ice skates and test her own ...

MS patients are about twice as likely to develop restless legs syndrome than those without the disease, according to a study in Spain.